tirzepatide shortage news The FDA says the Zepbound is over. That's rattling the weight loss industry US judge sides with FDA's

Every key point ties back to primary sources, including the FDA prescribing information and the pivotal weight-loss trial evidence published in PubMed

Asia Pacific GLP-1 Receptor Agonist Market: Asia Pacific is registered the fastest growth rate during the forecasted period driven by Rising prevalence of diabetes and obesity, approvals for new indications or formulations, and increasing healthcare access in emerging markets

*Correspondence: Wan-Chun Li, [email protected] These authors have contributed equally to this work This article was submitted to Diabetes Therapies, a section of the journal Frontiers in Clinical Diabetes and Healthcare Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

10.1002/pro.4499 32 LeT